Drugs / Teneligliptin
Trials 28
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT04431141 | Sep → Nov 2020 | type 2 diabetes mellitus | Handok Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03769870 | Jan → Feb 2019 | diabetes mellitus | Handok Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03009513 | Jan → May 2017 | diabetes mellitus | Handok Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03787043 | May → Jun 2014 | — | Handok Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03787017 | Jan → Aug 2014 | — | Handok Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00971243 | Aug 2009 → Apr 2011 | type 2 diabetes mellitus | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00628212 | Jan → Dec 2008 | type 2 diabetes mellitus | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 314 trials · 2 met primary | ||||||
| Phase 3 | NCT05504226 | Oct 2022 → Nov 2023 | type 2 diabetes mellitus | Handok Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05504239 | Sep 2022 → Apr 2024 | type 2 diabetes mellitus | Handok Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02924064 | Sep 2016 → Sep 2018 | type 2 diabetes mellitus | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02916706 | Sep 2016 → Aug 2018 | type 2 diabetes mellitus | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02567994 | Apr 2015 → Oct 2017 | type 2 diabetes mellitus | Handok Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02354222 | Jan 2015 → Feb 2016 | type 2 diabetes mellitus | Tanabe Pharma Corporation | Completed | Met primary |
| Phase 3 | NCT01798238 | Nov 2012 → May 2014 | type 2 diabetes mellitus | Handok Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01805830 | May 2012 → May 2013 | type 2 diabetes mellitus | Handok Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01301833 | Feb 2011 → Sep 2012 | type 2 diabetes mellitus | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01072331 | Feb → Aug 2010 | type 2 diabetes mellitus | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01026194 | Dec 2009 → Jun 2011 | type 2 diabetes mellitus | Tanabe Pharma Corporation | Completed | Met primary |
| Phase 3 | NCT00998881 | Sep 2009 → Jun 2010 | type 2 diabetes mellitus | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00974090 | Sep 2009 → Mar 2011 | type 2 diabetes mellitus | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02314637 | Aug 2009 → Jul 2011 | type 2 diabetes mellitus | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 47 trials · 2 met primary | ||||||
| Phase 4 | NCT04446026 | Jul → Dec 2020 | type 2 diabetes mellitus | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT03508323 | Apr 2018 → Dec 2019 | type 2 diabetes mellitus | Handok Inc. | Completed | Met primary |
| Phase 4 | NCT03011177 | Jan 2017 → Sep 2018 | type 2 diabetes mellitus | Handok Inc. | Completed | No outcome recorded |
| Phase 4 | NCT02512523 | Aug 2015 → Sep 2016 | type 2 diabetes mellitus | Handok Inc. | Completed | No outcome recorded |
| Phase 4 | NCT02449330 | Jun 2015 → Jun 2020 | type 2 diabetes mellitus | National Cerebral and Cardiovascular Center, Japan | Unknown | No outcome recorded |
| Phase 4 | NCT02312427 | Jan 2015 → Mar 2016 | congestive heart failure, diabetes mellitus | Mitsui Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02081599 | Jan 2014 → Jan 2016 | type 2 diabetes mellitus | Tanabe Pharma Corporation | Completed | Met primary |
| Comparator or background therapy7 trials | ||||||
| Phase 1 | NCT07102719 Comparator | Sep → Oct 2025 | — | Handok Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06889350 Comparator | Mar → Apr 2025 | — | Handok Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06339788 Comparator | May → Jun 2024 | — | Handok Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02354235 Background | Jan 2015 → Jan 2016 | type 2 diabetes mellitus | Tanabe Pharma Corporation | Completed | Met primary |
| Phase 3 | NCT02220907 Background | Aug 2014 → Feb 2016 | type 2 diabetes mellitus | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 4 | NCT03014479 Comparator | Feb → Oct 2017 | type 2 diabetes mellitus | Takeda | Completed | Missed primary |
| Phase 4 | NCT02528019 Comparator | Aug 2015 → Aug 2017 | — | Kurume University | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-06-26 | Tanabe Pharma Corporation | Regulatory Regulatory Approval of CANALIA® Tablets, type 2 diabetes mellitus treatment agent in Thailand tanabe-pharma.com ↗
Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; Representative Director, CEO: Akihisa Harada; hereinafter "Tanabe Pharma") announced today that on June 24th, 2026, Mitsubishi Tanabe Pharma (Thailand) Co., Ltd. (hereinafter “MTTH”) received Marketing Authorization for CANALIA® Tablets, a type 2 diabetes mellitus treatment agent that combines selective DPP-4 inhibitor TENELIA® Tablets (generic name: teneligliptin) and SGLT2 inhibitor CANAGLU® Tablets (generic name: canagliflozin) in Thailand. |
| 2024-02-20 | Tanabe Pharma Corporation | Regulatory Application for Additional Dosage Form of CANALIA® Combination OD Tablets, Selective DPP-4 inhibitor/SGLT2 inhibitor Combination Drug tanabe-pharma.com ↗
Application for Additional Dosage Form of CANALIA® Combination OD Tablets, Selective DPP-4 inhibitor/SGLT2 inhibitor Combination Drug |
| 2019-09-24 | Tanabe Pharma Corporation | Regulatory NMPA accepts our filing for TENELIA, a treatment agent for type 2 diabetes mellitus in China tanabe-pharma.com ↗
NMPA accepts our filing for TENELIA, a treatment agent for type 2 diabetes mellitus in China |
| 2012-06-29 | Tanabe Pharma Corporation | Regulatory Marketing and Manufacturing Approval Received for TENELIA® 20mg Tablets A DPP-4 Inhibitor for Type 2 Diabetes Mellitus Originating from Japan tanabe-pharma.com ↗
Mitsubishi Tanabe Pharma Corporation (hereafter, Mitsubishi Tanabe; Head Office: Chuo-ku, Osaka; President & CEO: Michihiro Tsuchiya) and Daiichi Sankyo Co., Ltd., (hereafter, Daiichi Sankyo; Head Office: Chuo-ku, Tokyo; President & Representative Director: Joji Nakayama) announced today that Mitsubishi Tanabe has received approval to manufacture and market the selective DPP-4 inhibitor TENELIA ® 20mg tablets (generic name: Teneligliptin hydrobromide hydrate) in Japan. |
| 2011-09-01 | Tanabe Pharma Corporation | Regulatory New Drug Application Filed in Japan for MP-513 a Type 2 Diabetes Treatment tanabe-pharma.com ↗
Mitsubishi Tanabe Pharma Corporation (President & CEO: Michihiro Tsuchiya) announced that the Company filed to the Ministry of Health, Labor and Welfare an application for the manufacturing and marketing approval of MP-513 (generic name: teneligliptin), a type 2 diabetes treatment that has been developed in Japan. |
All press releases naming this drug 6 releases
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 36 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | teneligliptin | “Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind,...” PMID 22776014 ↗ Jul 201231“DPP-4 inhibitor (sitagliptin, vildagliptin, alogliptin, linagliptin, teneligliptin, anagliptin or saxagliptin) will be suspended for one month and serum BNP will be measured.” NCT02312427 ↗ “The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) in combination with Sulfonylurea in patients with type 2 Diabetes” NCT00974090 ↗ “Alogliptin, anagliptin, linagliptin, saxagliptin, sitagliptin, teneligliptin or vildagliptin” NCT03014479 ↗ “Teneligliptin(MP-513) vs. Placebo in Patient With Metformin Monotherapy” NCT01805830 ↗ “Single does administration of Teneligliptin and Empagliflozin High” NCT06889350 ↗ “Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus” NCT01798238 ↗ “teneligliptin (20-40mg)” NCT02528019 ↗ |
| Known as | MP-513 | “The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) as monotherapy or in combination with Sulfonylurea (glimepiride) in Japanese patients...” NCT02314637 ↗8“The purpose of this study is to evaluate the efficacy and safety of MP-513 (Teneligliptin) in combination with thiazolidinedione (pioglitazone)” NCT01026194 ↗ “Teneligliptin(MP-513) vs. Placebo in Patient With Metformin Monotherapy” NCT01805830 ↗ “Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus” NCT01798238 ↗ “MP-513 (Teneligliptin)” NCT02924064 ↗ “MP-513 (Teneligliptin)” NCT02916706 ↗ |
| Known as | Teneli | “Drug: Teneli (Teneligliptin)” NCT02081599 ↗ |
| Known as | Teneligliptin Hydrobromide | “Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet” NCT05504239 ↗1“Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet” NCT05504226 ↗ |
| Known as | Teneligliptina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2147777 ↗ |
| Known as | Teneligliptine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2147777 ↗ |
| Action | Inhibit | “teneligliptin 10 and 20 mg, a novel dipeptidyl peptidase-4 inhibitor” PMID 22776014 ↗ Jul 20121“Dipeptidyl peptidase IV inhibitor” CHEMBL2147777 ↗ |
| Modality | Small molecule | — CHEMBL2147777 ↗ |
| Route | Oral | “Teneligliptin 10 mg, orally, once daily” NCT00628212 ↗ |
| Target | DPP4 | “Dipeptidyl peptidase IV inhibitor” CHEMBL2147777 ↗ |